<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="125988">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01806974</url>
  </required_header>
  <id_info>
    <org_study_id>RC12_0172</org_study_id>
    <nct_id>NCT01806974</nct_id>
  </id_info>
  <brief_title>Consequences of Anti-interleukin 6 Immunotherapy Treatment for Rheumatoid Arthritis on Periodontium</brief_title>
  <acronym>ParoPAR</acronym>
  <official_title>Multicenter, Prospective Study, on the Consequences of Anti-interleukin 6 Immunotherapy Treatment for Rheumatoid Arthritis on: - Healthy and Pathological Periodontium - The Level of Expression of Some Markers of Inflammation and Periodontal Pathogenic Bacteria in Periodontal Sulci and Periodontal Pockets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <authority>FRANCE : ANSM (Agence National de Sécurité du Médicament et des produits de santé)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rheumatoid arthritis and periodontitis are two inflammatory diseases that share many
      pathophysiological similarities as some inflammatory mediators like TNF-alpha, IL-1, Il-6,
      Il-17, Il-12 et Il-17, RANK-L, or OPG The most severe or progressive forms of rheumatoid
      arthritis require in 10-30% of cases, the use of biotherapies such as anti-TNF-alpha, anti
      CD-20 and anti-lL-6. All these treatments results in, among other things, an increased risk
      of infection, both viral and bacterial.

      These new biotherapies could have an impact on periodontal status

        -  either by favouring sub gingival colonization of root surfaces by periodontal
           pathogenic bacteria and initiate periodontitis or exacerbate pre-existing
           periodontitis,

        -  or a positive modulation of the host response by inhibiting bone resorption of the
           alveolar process.

      To date, very few studies have been conducted on this subject which is really a
      translational research, involving several medical specialties.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Clinical attachment level</measure>
    <time_frame>6 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Gain or loss obtained by periodontal probing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection of periodontopathogenic germs</measure>
    <time_frame>6 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Detection of periodontopathogenic germs by RT - PCR - Q wich the bacterial samples will be made at the outset of the study and 6 month after the beginning of anti IL6 treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of periodontopathogenic germs</measure>
    <time_frame>6 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Quantification of periodontopathogenic germs by RT - PCR - Q wich the bacterial samples will be made at the outset of the study and 6 month after the beginning of anti IL6 treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of inflammation markers in the gingival fluid</measure>
    <time_frame>6 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Detection and quantification of inflammation markers in the gingival fluid : IL-1, IL-6, IL-8, IL-10, IL-12, IL-15, IL-17, TGF- beta, TNF-alpha, IL-4 et IFn-gamma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of inflammation markers in the gingival fluid</measure>
    <time_frame>6 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Quantification of inflammation markers in the gingival fluid : IL-1, IL-6, IL-8, IL-10, IL-12, IL-15, IL-17, TGF- beta, TNF-alpha, IL-4 et IFn-gamma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of inflammation</measure>
    <time_frame>6 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of inflammation through Bleeding On Probing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of oral hygiene level</measure>
    <time_frame>6 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of oral hygiene level with plaque Index</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">47</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Periodontitis</condition>
  <arm_group>
    <arm_group_label>patient with parodontitis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient with rheumatoid arthritis and pparodontitis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient without parodontitis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient with rheumatoid arthritis but periodontally healthy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>oral exam and</intervention_name>
    <description>The study will be conducted with patient presenting a rheumatoid arthritis and for which an anti IL6 biotherapy treatment is planned. Each patient will benefit a record oral exam that will evaluate his periodontal status and on a possible periodontitis associated. Bacterial samples and cytokine will be realized (in defined periodontal pocket or in the most affected periodontal pocket depending of the periodontal status of patients) before the IL6 biotherapy and 6 month after. A periodontal charting will be realized at the same time.</description>
    <arm_group_label>patient with parodontitis</arm_group_label>
    <arm_group_label>Patient without parodontitis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient over 18 years presenting a rheumatoid arthritis and for which an anti IL6
             biotherapy treatment is prescribed.

          -  At least 18 permanent teeth in the mouth at least 3 teeth with a healthy periodontal
             status

          -  Having expressed their written free and informed consent

        Exclusion Criteria:

          -  Hypersensitivity to any of the following components : tocilizumab, saccharose,
             polysorbate 80, phosphate disodique dodécahydrate, phosphate monosodique dehydrate

          -  Severe or active infections

          -  Systemic Pathology affecting the immune system including Sjögren's syndrome

          -  Surgery in the previous month

          -  HIV positive

          -  Alcoholic

          -  Toxicoman

          -  Antibiotic treatment in the last 2 months

          -  Legally protected patients
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Assem SOUEIDAN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes UH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Assem SOUEIDAN, PhD</last_name>
    <email>assem.soueidan@chu-nantes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brest University Hospital</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julien DEMOERSMAN</last_name>
    </contact>
    <investigator>
      <last_name>Jacques-Olivier PERS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien DEMOERSMAN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alain SARAUX</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Assem SOUEIDAN</last_name>
      <email>assem.soueidan@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Yves MAUGARS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zahi BADRAN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Céline BORIES</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean Marie BERTHELOT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joëlle GLEMAREC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Assem SOUEIDAN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 2, 2013</lastchanged_date>
  <firstreceived_date>March 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Periodontitis</keyword>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>anti-interleukin 6</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>inflammation</keyword>
  <keyword>bacteria</keyword>
  <keyword>periodontal sulci</keyword>
  <keyword>periodontal pockets</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Periodontal Pocket</mesh_term>
    <mesh_term>Periodontitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
